Ramucirumab + MEDI4736
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Cancer
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
Trial Timeline
Feb 19, 2016 → Jan 13, 2021
NCT ID
NCT02572687About Ramucirumab + MEDI4736
Ramucirumab + MEDI4736 is a phase 1 stage product being developed by Eli Lilly for Gastric Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02572687. Target conditions include Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02572687 | Phase 1 | Completed |
Competing Products
20 competing products in Gastric Cancer